News archive

The Joint Research Center of the European Union (JRC) and the European Partnership for Alternatives to Animal testing (EPAA) recently held an informational webinar on their designathon for the use of human-specific methods in systemic toxicity.

A research group led by Prof. Dr. Anne Spang of the Biozentrum of the University of Basel has investigated the lipid metabolism process in yeast cells and human cells. The team found that a protein called Arf1 influences when and how much stored fat is converted into energy.

To analyze malaria disease mechanisms and explore better treatment options, Hesperos, a company based in Orlando, Florida, has developed a malaria disease model on a chip that integrates four human tissue constructs. New treatments are urgently needed because the malaria pathogen has become resistant to drugs. To find new drugs more quickly and effectively, organ-on-a-chip technologies may be well suited.

As published online in Nature in late June, a study suggests that although the beginnings of multiple sclerosis are based on autoimmune disease, the progression of the disease in individual patients depends partly on how well the brain copes with the autoimmune attack.

Adiposity research with cells

Thursday, 06 July 2023 10:25

A team of researchers led by Prof. Dr. Anne Spang from the Biozentrum of the University of Basel has studied the lipid metabolism process in yeast cells and human cells in more detail. They have discovered that the protein Arf1 (ADP-ribosylation factor 1) acts like a molecular switch to regulate how many lipids are converted into ATP in the body.

Scientists at the Wyss Institute at Harvard University in Boston have recreated a model of reflux disease (barrett's disease) in vitro. The goal is to gain a better understanding of the cellular and molecular triggers of this disease and to develop appropriate drug therapies.

This year's World Summit on Microphysiological Systems was held in Berlin from June 26 to 30. 1,297 participants from numerous countries had registered. It was impressive to see how many young scientists dedicated themselves to the development of animal-free methods with the ultimate goal of finding better treatments through human-specific research, reducing the financial burden and time required to do so, and replacing animal experimentation.

Dr. Eckhard von Kreutz, former senior vice president and head of translational sciences at Bayer Pharmaceuticals, recently described on the LinkedIN platform eight steps necessary to completely replace animal testing.

The Jena-based biotechnology company Dynamic42, a spin-off from the Center for Sepsis Control and Care (CSCC) at Jena University Hospital, has reached a milestone. It has secured growth financing from bm-t Beteiligungsmanagement Thüringen GmbH (bm-t) and another financier.

DNTOX GmbH, based in Düsseldorf, Germany, is a bio-analytical testing laboratory that screens chemicals for its potential to disrupt human brain development and cause developmental neurotoxicity (DNT) without using animals. With its service, the research team has convinced investors and can now dispose of 1.4 million euros in start-up funding.